A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

Korábbi kezelés

• Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment
• Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial.
• Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice

Más betegség

• patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement.

Egyéb

• Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC).
• Pregnant or lactating women.

• Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.
• Benralizumab has been prescribed according to the approved label and local reimbursement criteria
• Provision of signed Informed Consent Form (ICF) prior to any study-related activities
• Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).